SCHEMBL1346680

SCHEMBL1346680

O=C(c1ccccc1)P(C(=O)c1ccccc1)C(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 5/20 0.55
CES2 O00748 5/20 0.55
TSHR P16473 3/20 0.55
ALDH1A1 P00352 3/20 0.55
DAO P14920 1/20 0.55
NAPRT Q6XQN6 1/20 0.55
TDP1 Q9NUW8 4/20 0.50
CYP3A4 P08684 2/20 0.50
MAPT P10636 2/20 0.50
CA2 P00918 2/20 0.50
CA4 P22748 2/20 0.50
HSD17B10 Q99714 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA9 Q16790 2/20 0.50
POLB P06746 1/20 0.50
PARP1 P09874 1/20 0.50
CYP2C19 P33261 1/20 0.50
RECQL P46063 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21352312 0.83 CES1 (0.44) CES1CES2TSHRALDH1A1DAO
SCHEMBL543379 0.80 CES1 (0.52) CES1CES2TSHRALDH1A1DAO
SCHEMBL27510084 0.78 CES1 (0.50) CES1CES2TSHRALDH1A1DAO
SCHEMBL4417015 0.78 CES1 (0.50) CES1CES2TSHRALDH1A1DAO
SCHEMBL1608946 0.76 CES1 (0.48) CES1CES2TSHRALDH1A1DAO
SCHEMBL28143072 0.76 CES1 (0.48) CES1CES2TSHRALDH1A1DAO
SCHEMBL5164356 0.76 CES1 (0.48) CES1CES2TSHRALDH1A1DAO
Benzophenone SCHEMBL29023256 0.75 ALDH1A1 (0.93) CES1CES2TSHRALDH1A1DAO
Benzophenone SCHEMBL28761922 0.75 ALDH1A1 (0.93) CES1CES2TSHRALDH1A1DAO
SCHEMBL4353525 0.74 CES1 (0.64) CES1CES2TSHRALDH1A1DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266409-B1 Process for group III-V semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2019-04-23 US claimed
US-8884273-B1 Process for group III-V semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2014-11-11 US claimed
US-7557028-B1 For example, making indium phosphide (InP)semiconductors starting from tribenzoyl phosphine and tris-cyclopentadienyl indium; use in photovoltaic devices and light emitting diodes NANOSYS, INC. (US) 2009-07-07 US claimed
US-10266409-B1 Process for group III-V semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2019-04-23 US disclosed
US-10029972-B2 Use of heteroleptic indium hydroxides as precursors for INP nanocrystals NANOSYS, INC. (US) 2018-07-24 US disclosed
US-9884763-B1 Process for group III-V semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2018-02-06 US disclosed
US-9688534-B1 Process for group III-V semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2017-06-27 US disclosed
US-20170137360-A1 USE OF HETEROLEPTIC INDIUM HYDROXIDES AS PRECURSORS FOR INP NANOCRYSTALS SHOEI CHEMICAL INC. (JP) 2017-05-18 US disclosed
WO-2017083483-A1 USE OF HETEROLEPTIC INDIUM HYDROXIDES AS PRECURSORS FOR INP NANOCRYSTALS NANOSYS, INC. (US) 2017-05-18 WO disclosed
US-9469538-B1 Process for group III-IV semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2016-10-18 US disclosed
US-8884273-B1 Process for group III-V semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2014-11-11 US disclosed
US-8062967-B1 Process for group III-V semiconductor nanostructure synthesis and compositions made using same NANOSYS, INC. (US) 2011-11-22 US disclosed
US-7557028-B1 For example, making indium phosphide (InP)semiconductors starting from tribenzoyl phosphine and tris-cyclopentadienyl indium; use in photovoltaic devices and light emitting diodes NANOSYS, INC. (US) 2009-07-07 US disclosed
EP-0779891-B1 NOVEL ACYLPHOSPHINE OXIDES CIBA GEIGY AG (CH) 1998-12-23 EP disclosed
US-5721292-A PHOTOPOLYMERIZATION INITIATOR CIBA SPECIALTY CHEMICALS CORPORATION (US) 1998-02-24 US disclosed
EP-0805159-A1 Phosphorus containing alkyl or arylsulphonyl derivatives and method for preparing same Cytec Canada Inc. (CA) 1997-11-05 EP disclosed
EP-0779891-A1 NOVEL ACYLPHOSPHINE OXIDES Ciba SC Holding AG (CH) 1997-06-25 EP disclosed
WO-1996007662-A1 NOVEL ACYLPHOSPHINE OXIDES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1996-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10029972-B2 Use of heteroleptic indium hydroxides as precursors for INP nanocrystals INPP5A, INPP5B, INPPL1 CES1 4699/4885CES2 3332/4885TSHR 4710/4885
US-20170137360-A1 USE OF HETEROLEPTIC INDIUM HYDROXIDES AS PRECURSORS FOR INP NANOCRYSTALS INPP5A, INPP5B, INPPL1 CES1 4699/4885CES2 3332/4885TSHR 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.